-
The Role of OX40-OX40L Axis in the Pathogenesis of Atopic Dermatitis. Dermatitis (IF 5.2) Pub Date : 2024-05-03 Natale Schettini, Lucrezia Pacetti, Monica Corazza, Alessandro Borghi
OX40 is a co-stimulatory immune checkpoint molecule that promotes the activation and the effector function of T lymphocytes through interaction with its ligand (OX40L) on antigen-presenting cells. OX40-OX40L axis plays a crucial role in Th1 and Th2 cell expansion, particularly during the late phases or long-lasting response. Atopic dermatitis is characterized by an immune dysregulation of Th2 activity
-
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab. Dermatitis (IF 5.2) Pub Date : 2024-04-26 Filomena Russo, Vittoria Cioppa, Laura Lazzeri, Nicola Milanesi, Marco Galluzzo, Angelo Massimiliano D'Erme, Natale Schettini, Barbara Cocuroccia, Donatella Sordi, Annarita Panebianco, Marina Talamonti, Claudia Paganini, Ornella De Pità, Anna Rita Giampetruzzi, Giovanni Luca Scaglione
Background and Objective: Atopic Dermatitis (AD) is the most prevalent inflammatory skin disorder resulting in an intense impact on patients quality of life. The aim of this study is to evaluate the clinical meaning of the DLQI scores documented between different phenotypes of AD patients under biologic therapy with Dupilumab. Method: We conducted a retrospective analysis of 209 patients with AD treated
-
Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens. Dermatitis (IF 5.2) Pub Date : 2024-04-17 Syed Minhaj Rahman, Yousef Salem, Aamir Hussain
Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes
-
Correlation of Disease Severity, Proinflammatory Cytokines, and Reduced Brain Gray Matter Volumes in Patients with Atopic Dermatitis. Dermatitis (IF 5.2) Pub Date : 2024-04-17 Cheng-Yuan Li, Wan-Chen Chang, Mu-Hong Chen, Pei-Chi Tu, Tai-Li Chen, Chih-Chiang Chen, Yun-Ting Chang, You-Yin Chen, Ya-Mei Bai
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease. However, few studies have investigated brain changes associated with chronic inflammation. We hypothesized that chronic inflammation might be related to brain structural alterations in patients with AD. Objectives: To investigate the association between disease severity (Eczema Area and Severity Index [EASI]), proinflammatory
-
Patient-Reported Association Between COVID-19 Infection or Vaccination and Onset of Allergic Contact Dermatitis. Dermatitis (IF 5.2) Pub Date : 2024-03-27 Nicholas Battis, Samuel F Ekstein, Eric Eugene Paul Cosky, Anne B Neeley
Background: Over the course of the COVID-19 pandemic, our clinic has encountered numerous patients who report that either COVID-19 vaccination or infection was the precipitating event for their development of allergic contact dermatitis (ACD). Up to this time, there is no formal investigation regarding COVID-19 vaccination or infection causing ACD. However, there have been several registry-based case
-
Patient and Caregiver Perspectives on the Relationship Between Atopic Dermatitis Symptoms and Mental Health. Dermatitis (IF 5.2) Pub Date : 2024-03-14 Jessica K Johnson, Allison Loiselle, Sheena Chatrath, Wendy Smith Begolka
Background: Atopic dermatitis (AD) patients have increased likelihood of developing depression and anxiety. The patient and caregiver's perceptions of the correlation of mental health (MH) and AD symptoms are not well understood. Objective: To evaluate patient-reported MH symptoms and their correlation with AD disease severity and understand patient-perceived associations of AD with impacts to their
-
Cheilitis: A Diagnostic Algorithm and Review of Underlying Etiologies. Dermatitis (IF 5.2) Pub Date : 2024-02-29 Deepika Narayanan, Megan Rogge
Cheilitis, or inflammation of the lips, is a common reason for dermatologic consultation. The inflammation can include the vermillion lip, vermillion border, and surrounding skin, and can present with an acute or chronic course. There are many etiologies, including irritant and allergic contact dermatitis, atopic cheilitis, actinic cheilitis, infectious etiologies, nutritional deficiencies, drug-induced
-
Lime Dermatitis. Dermatitis (IF 5.2) Pub Date : 2024-02-22 Jihane Belcadi, Sara Oulad Ali, Karima Senouci
Phytophotodermatitis are skin eruptions caused by contact with a plant substance and exaggerated by exposure to sunlight. They are due to the presence of furocoumarins (psoralens, xanthotoxins, and bergaptenes) in the plant and involve 2 mechanisms of skin photosensitivity: phototoxicity or photoallergy.
-
Allergic Contact Dermatitis to Octyl Cyanoacrylate Skin Glue After Surgical Wound Closure: A Systematic Review. Dermatitis (IF 5.2) Pub Date : 2024-02-21 Chaitanya Dev Pannu, Kamran Farooque Md
The rising incidence of allergic contact dermatitis (ACD) after cyanoacrylate adhesive use necessitates a comprehensive understanding of its clinical presentations, risk factors, and management. In this systematic review, we conducted an exhaustive search following PRISMA guidelines within Medline and PubMed databases to identify studies reporting cases of ACD resulting from cyanoacrylate adhesive
-
Allergic Contact Dermatitis to Linalool Hydroperoxides: Pitfalls in the Diagnostic Process-Findings from a Repeated Open Application Test Study. Dermatitis (IF 5.2) Pub Date : 2024-02-21 Thanisorn Sukakul, Magnus Bruze, Martin Mowitz, Anna Kiuru, Cecilia Svedman
Background: Increasing trends of oxidized linalool contact allergy have been reported. However, the impact of reactivity and dose in eliciting allergic contact dermatitis caused by linalool hydroperoxides is insufficiently investigated. Objectives: To perform repeated open application tests (ROATs) using the real-world concentrations of linalool hydroperoxides in patients and control participants.
-
Impact of Atopic Dermatitis on Quality of Life of Caregivers: A Systematic Review and Meta-Analysis. Dermatitis (IF 5.2) Pub Date : 2024-02-16 John Chun Hian Yap, Yik Weng Yew
Abstracts: Background: Atopic dermatitis (AD) is a chronic dermatological condition that affects both patients and their caregivers. Aims: To summarize evidence on the impact of AD on the quality of life (QoL) of caregiver. Methods: Observational studies were searched for in Medline, Embase, Cochrane Library, SCOPUS, and CINAHL databases up till March 1, 2023. Results: Seventy studies with a total
-
Pediatric Patch Testing at Mayo Clinic Between 2016 and 2020. Dermatitis (IF 5.2) Pub Date : 2024-02-06 Katherine L Wang, Erin M Rainosek, Yul W Yang, Hafsa M Cantwell, Lisa A Drage, James A Yiannias, Mark D P Davis, Matthew R Hall, Molly J Youssef
Background: Allergic contact dermatitis (ACD) is a common condition within the pediatric population. Patch testing is an important way to identify relevant allergens. Objective: To provide an update of the common contact allergens seen in children based on patch testing data at our institution from 2016 to 2020. Methods: We performed a retrospective analysis of patch test data from children aged 1-18
-
Nonsteroidal Approaches for Atopic Dermatitis: A Clinical Update. Dermatitis (IF 5.2) Pub Date : 2024-02-06 Peter Y Ch'en, Peter A Lio
Topical corticosteroids (TCSs) are the most widely used treatment for atopic dermatitis (AD), but they can have adverse effects such as skin atrophy, telangiectasias, and hypopigmentation, especially with prolonged use of higher potency steroids. Many patients also have a fear of using TCSs, known as "corticophobia." With the development of biologics and Janus kinase inhibitors, a nonsteroidal approach
-
Allergic or Not: Final Interpretation of Doubtful Patch Test Reactions From the North American Contact Dermatitis Group, 2019-2020. Dermatitis (IF 5.2) Pub Date : 2024-02-06 Margo J Reeder, Aman Nihal, Srikanth R Aravamuthan, Erin M Warshaw, Joel G DeKoven, Amber R Atwater, Marie-Claude Houle, Brandon L Adler, Jonathan I Silverberg, James S Taylor, Melanie D Pratt, Donald V Belsito, Jiade Yu, Nina B Botto, Chris M Mowad, Cory A Dunnick, Vincent A DeLeo
Background: Doubtful patch test reactions generally do not meet criterion for positivity in patch testing. However, the North American Contact Dermatitis Group (NACDG) allows for doubtful reactions to be coded with a final determination of "allergic/positive" based on the temporal pattern, appearance, known characteristics of the allergen, and/or other supportive patch test reactions. Objectives: To
-
Supplemental Patch Testing Identifies Allergens Missed by Standard Screening Series. Dermatitis (IF 5.2) Pub Date : 2024-01-29 Amber Reck Atwater, Beiyu Liu, Rabina Walsh, Raina Bembry, Jordan Maxwell Ward, Cynthia L Green
Background: Supplemental patch testing is an adjunct to standard patch test screening series. Objective: To determine the demographics, characteristics, frequency, relevance, and interpretation of patch test reactions for supplemental patch testing. Methods: Retrospective study of patients tested 2017-2020 with North American Contact Dermatitis Group (NACDG) and supplemental screening series (Supplemental
-
Tofacitinib: A Treatment Option for Recalcitrant Polymorphic Light Eruption and Its Mechanistic Rationale. Dermatitis (IF 5.2) Pub Date : 2024-01-23 Kabir Sardana, Sinu Rose Mathachan, Ananta Khurana
Background: Polymorphous light eruption is largely characterized by a delayed-type (type IV) hypersensitivity reaction to 1 or more undefined endogenous ultraviolet-induced skin antigens. Objectives: To evaluate the efficacy of tofacitinib in refractory cases of polymorphous light eruption. Methods: Seven patients who had failed multiple systemic treatments or relapsed within 2 weeks of existing systemic
-
The Fracture Risk of Elderly Patients With Atopic Dermatitis. Dermatitis (IF 5.2) Pub Date : 2024-01-16 Yu-Yu Hsiao, Yi-Hsing Chen, Yun-Wen Chen, Kuo-Tung Tang
Background: A higher fracture risk has been reported previously in patients with atopic dermatitis (AD). The bone mineral density (BMD) was not accounted for in these studies. Objective: To investigate the fracture risk in AD patients after adjustment for factors including BMD. Methods: We retrospectively analyzed AD patients (≥45 years) who underwent BMD examination at our hospital from July 2010
-
Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis. Dermatitis (IF 5.2) Pub Date : 2024-01-11 Linda F Stein Gold, Wynnis L Tom, Vivian Shi, Paul Sanders, Chuanbo Zang, Bonnie Vlahos, Amy Cha
Background: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of patients with mild-to-moderate atopic dermatitis (AD). Objective: To assess the efficacy and safety of crisaborole in patients with AD who had received prior treatment with (a) corticosteroids (systemic or topical) or topical calcineurin inhibitors (TCIs) or (b) topical corticosteroids (TCSs)
-
Overcoming False-Negative Patch Tests: A Systematic Literature Review. Dermatitis (IF 5.2) Pub Date : 2024-01-05 Shayan Massoumi, Zehra Rizvi, Ulysses Cázares, Howard Maibach
Exogenous allergens, found in cosmetic products, jewelry items, antiseptics and antibacterials, plants, and solvents, can cause clinical allergic contact dermatitis (ACD). To help identify and discern which allergen is causing ACD, clinicians use patch tests, but they can yield false-negative results at times. Examining potential reasoning for false negatives is particularly helpful when a patient's
-
Risk Factors of Onset Time and Persistence of Atopic Dermatitis in Children Under Age 5 Years: A Cross-Sectional Study. Dermatitis (IF 5.2) Pub Date : 2023-12-22 Kuangnan Song, Yuyan Zhang, Liang Wang, Siping Zhang
Background: The prevalence of atopic dermatitis (AD) is high among children, with development of AD occurring during early childhood in most affected children and some having a chronic disease course. Risk factors for AD in this group remain undefined. Objectives: We analyzed the medical records of children with AD under 5 years of age. We summarized characteristics of the natural course of AD in these
-
Adverse Cosmetic Reactions in a Pediatric Population Reported to the Chongqing Drug Administration in China From 2017 to 2021. Dermatitis (IF 5.2) Pub Date : 2023-12-21 Sha Wang, Jing Lyu, Yang Jiang, Jiajia Li, Qingchun Diao
Background: Despite their ubiquitous use and several safety incidents involving cosmetics for children in China, there is little research on adverse reactions to cosmetics in children. Objectives: We assessed the cosmetic adverse reactions (CARs) reports submitted to the Chongqing Drug Administration in China for children, to understand the characteristics of CARs in a pediatric population and determine
-
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis. Dermatitis (IF 5.2) Pub Date : 2023-12-18 Jonathan I Silverberg, Marjolein de Bruin-Weller, Brian M Calimlim, Xiaofei Hu, Sarah A Ofori, Andrew M Platt, Henrique D Teixeira, Kilian Eyerich, Jacob P Thyssen
Background: In patients with moderate-to-severe atopic dermatitis (AD), greater skin clearance and itch reduction are associated with more pronounced improvements in quality of life (QoL). Objective: To characterize the aggregate response benefit with upadacitinib versus dupilumab or placebo in patients with moderate-to-severe AD. Methods: Degree of skin clearance and itch response in 3 phase 3 studies
-
Toxic Ingredients in Personal Care Products: A Dermatological Perspective. Dermatitis (IF 5.2) Pub Date : 2023-12-18 Rachel R Lin, Deborah A Lin, Andrea D Maderal
Environmental dermatology is the study of how environmental factors affect the integumentary system. The environment includes natural and built habitats, encompassing ambient exposure, occupational exposures, and lifestyle exposures secondary to dietary and personal care choices. This review explores common toxins found in personal care products and packaging, such as bisphenols, parabens, phthalates
-
Patch Testing With Nickel, Cobalt, and Chromium in Patients With Suspected Allergic Contact Dermatitis. Dermatitis (IF 5.2) Pub Date : 2023-12-04 Jonathan I Silverberg, Nisha Patel, Erin M Warshaw, Joel G DeKoven, Donald V Belsito, Amber R Atwater, James S Taylor, Denis Sasseville, Margo J Reeder, Marie-Claude Houle, Vincent A DeLeo, Howard I Maibach, Joseph F Fowler, Kathryn A Zug, Melanie D Pratt, JiaDe Yu, Christen M Mowad, Nina C Botto, Brandon L Adler
Background: Allergic contact dermatitis is frequently caused by metals, including multiple metals simultaneously. Objectives: To assess characteristics and associations of positive and clinically relevant patch test (PT) reactions with solitary and concurrent metal sensitization. Methods: A retrospective analysis of PT results for nickel, cobalt, and/or chromium from the North American Contact Dermatitis
-
Results of Patch Testing to Botanicals: Review of the Mayo Clinic Experience Over 2 Decades (1997-2017). Dermatitis (IF 5.2) Pub Date : 2023-11-24 Anagha Bangalore-Kumar, Mauricio F Jin, Hilary Kunkel, Nishad Sathe, Matthew R Hall, Lisa A Drage, Molly Youssef, Yul W Yang, James A Yiannias, Jill Killian, Mark D P Davis
Background: Botanicals are increasingly incorporated into skincare products. Although allergic contact dermatitis due to botanicals is recognized, data describing the prevalence of positive patch tests to botanicals are sparse. Objective: To report the Mayo Clinic experience of patch testing to selected botanical products in the standard, extended standard, fragrance, and plant series. Methods: IRB-approved
-
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors. Dermatitis (IF 5.2) Pub Date : 2023-11-14 Luca Potestio, Cataldo Patruno, Maddalena Napolitano
Background: Tralokinumab has been recently approved for the management of moderate-to-severe atopic dermatitis (AD). Despite its effectiveness and safety have been widely reported, there are no studies investigating factors that may affect clinical outcomes. Objective: To evaluate the effectiveness and safety of tralokinumab, also to investigate possible predictive response factors that may affect
-
Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up. Dermatitis (IF 5.2) Pub Date : 2023-10-26 Francisco José Navarro-Triviño, Manuel Galán-Gutiérrez, José Carlos-Armario Hita, Ricardo Ruiz-Villaverde, Javier Domínguez-Cruz, José Juan Pereyra-Rodríguez
Background: Hand-foot eczema (HFE) are special locations of dermatitis, which are often associated with atopic dermatitis (AD) and have a significant negative impact on the quality of life, demanding a clinically relevant improvement. Objectives: To evaluate the effectiveness and safety of dupilumab in the treatment of eczema localized in hands and/or feet in patients with moderate-to-severe AD. Methods:
-
A Survey of Skin Reactions Associated With Acrylic Nail Cosmetics, With a Focus on Home Kits: Is There a Need for Regulation? Dermatitis (IF 5.2) Pub Date : 2023-10-16 Jana Guenther, Thomas Norman, Choo Phei Wee, Brandon L Adler
Background: Sensitization to (meth)acrylates, the most common nail cosmetic allergens, is rising. In recent years, home acrylic nail kits have become easily available. Objective: To investigate the characteristics of individuals reporting skin reactions associated with acrylic nail cosmetics, particularly home kits. Methods: Cross-sectional survey of Facebook nail allergy support groups. Inclusion
-
Assessment of Contact Allergens in "Hypoallergenic" Athletic Shoes by Mass Spectrometry. Dermatitis (IF 5.2) Pub Date : 2023-10-11 Walter Liszewski, Benjamin Owen, Elise Fournier, Lillian Kerchinsky, Jason Wei, Andrew Scheman
Background: Identification of athletic shoes for patients with contact allergy is difficult. Company reports of allergen content are often incorrect. Objectives: To determine whether chemical analysis of 4 athletic shoes, previously reported to be free of the most common contact allergens, contain quantifiable allergen levels. Methods: Samples from the uppers and insoles of 4 shoes believed to be free
-
Topical Ectoin Versus Topical Dexpanthenol for Managing Acute Radiodermatitis Associated With Breast Cancer Radiotherapy: A Randomized Double-Blind Study. Dermatitis (IF 5.2) Pub Date : 2023-10-04 Nagwa E Abd Elazim, Sara M Awad, Maha S El-Naggar, Rania H Mohamed
Background: Radiodermatitis is a common side effect of breast cancer radiotherapy; however, there is no current consensus regarding an effective standard therapy. Objective: To evaluate the efficacy of topical ectoin versus dexpanthenol in the management of acute radiodermatitis after breast cancer radiotherapy. Methods: Fifty patients randomly used dexpanthenol 0.5% cream (25 patients), or ectoin
-
Poppers Dermatitis: A Systematic Review on a Unique Form of Contact Dermatitis in the MSM Community. Dermatitis (IF 5.2) Pub Date : 2023-10-03 Chavy Chiang, Nicholas Gessner, Anuk Burli, Walter Liszewski, Matthew Mansh, Cuong V Nguyen, Howa Yeung, John C Trinidad
There are certain demographic characteristics that may serve as risk factors for exposure to a contact allergen. Volatile alkyl nitrites, colloquially known as "poppers," are commonly inhaled by men who have sex with men (MSM) for their psychoactive and muscle-relaxing effects. They have been reported to cause either allergic contact dermatitis (ACD) or irritant contact dermatitis (ICD), termed "poppers
-
Characteristics of Litigations Involving Contact Dermatitis: An Exploratory Analysis. Dermatitis (IF 5.2) Pub Date : 2023-10-03 Aashka Suvarnakar, Rahul Raiker, Haig Pakhchanian, Kendall Jenkins, Aamir Hussain
Background: Contact dermatitis (CD) is one of the most common skin disorders, occurring in >20% of patients worldwide. Estimated cost burden for CD in the United States approaches $1 billion annually. Objective: To describe characteristics of litigation among patients with CD. Methods: Westlaw legal database for U.S. lawsuits was queried for lawsuits between the years 1983 and 2021 containing the keywords
-
Stasis Dermatitis: The Burden of Disease, Diagnosis, and Treatment. Dermatitis (IF 5.2) Pub Date : 2023-09-29 Gil Yosipovitch, J Mark Jackson, Susan T Nedorost, Adam J Friedman, Roni Adiri, Amy Cha, Juliana M Canosa
Stasis dermatitis (SD), an inflammatory dermatosis occurring on the lower extremities, is a cutaneous manifestation of chronic venous insufficiency (CVI). SD is associated with a significant burden of disease. Symptoms such as pain, swelling, and itching can be debilitating for patients, leading to poor sleep, loss of mobility, and the inability to perform daily activities, and can interfere with work
-
Successful Treatment of SAM Syndrome With Secukinumab Monotherapy: A Case Report of a 16-Month-Old Infant. Dermatitis (IF 5.2) Pub Date : 2023-09-28 Qiaoyu Cao, Jia Hou, Chaolan Pan, Li Zhang, Daian Cheng, Xiaochuan Wang, Ming Li
Severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome is a rare congenital skin disease. We report on a 16-month-old infant presenting with severe disseminated dermatitis, characterized by erythema and lichenified plaques. The crucial result of de novo missense mutation in the DSP gene (c.1769T>C, p.F590S) discovered by next-generation sequencing finally confirmed the diagnosis
-
Assessment and Management of Sleep Disturbances in Atopic Dermatitis: A Review. Dermatitis (IF 5.2) Pub Date : 2023-09-27 Archana Samynathan, Anna B Fishbein, Sabra M Abbott, Genery D Booster, Phyllis C Zee, Stephen H Sheldon, Gil Yosipovitch, Jonathan I Silverberg
Atopic dermatitis (AD) is a chronic burdensome inflammatory skin disease with well-established cutaneous and systemic comorbidities and disease burden. AD particularly has profound impacts on sleep in individuals of all ages. Sleep disturbances (SDs) affect 6.2% of school-age children and 33-87.1% of adults with AD. This narrative review addresses the burden of SD in AD patients, as well as biological
-
Pruritus and Pain Constitute the Main Negative Impact of Atopic Dermatitis From the Patient's Perspective: A Systematic Review. Dermatitis (IF 5.2) Pub Date : 2023-09-25 José Carlos Armario-Hita, Jose Manuel Carrascosa, Ángeles Flórez, Pedro Herranz, José Juan Pereyra-Rodríguez, Esther Serra-Baldrich, Juan Francisco Silvestre, Marta Comellas, Olga Isidoro, Francisco Javier Ortiz de Frutos
Atopic dermatitis (AD) is an inflammatory skin disease characterized by intense itching and highly visible signs, representing a great burden to the patient. Despite its straightforward diagnosis, AD severity and burden can be underestimated in routine clinical practice. This review aims to determine the impact of AD on patients' lives, establish which domains of life are most affected, and identify
-
Demonstration of Convolutional Neural Networks to Determine Patch Test Reactivity. Dermatitis (IF 5.2) Pub Date : 2023-09-12 Adarsh Ravishankar, Nicholas Heller, Paul L Bigliardi
Background: Convolutional neural networks (CNNs) have the potential to assist allergists and dermatologists in the analysis of patch tests. Such models can help reduce interprovider variability and improve consistency of patch test interpretations. Objective: Our aim is to evaluate the performance of a CNN model as a proof of concept in discriminating between patch tests with reactions and patch tests
-
Stratum Corneum Hydration As a Potential Marker of Response to Dupilumab in Atopic Dermatitis: A Prospective Observational Study. Dermatitis (IF 5.2) Pub Date : 2023-09-11 Trinidad Montero-Vilchez, Juan-Angel Rodriguez-Pozo, Carlos Cuenca-Barrales, Raquel Sanabria-de-la-Torre, Jesus-Manuel Torres-de-Pinedo, Salvador Arias-Santiago
Background: Dupilumab is an effective treatment for atopic dermatitis (AD) and it also restores skin barrier function. Nevertheless, early changes in epidermal barrier parameters related to sustained treatment response or treatment failure are not known. So, the objective of this study is to evaluate whether changes in skin barrier function after 16 weeks dupilumab treatment could predict sustained
-
Characteristics of DRESS Syndrome in the Elderly: A Comparative Study of 55 Patients. Dermatitis (IF 5.2) Pub Date : 2023-09-05 Emna Bahloul, Khaoula Trimeche, Khadija Sellami, Fatma Hammami, Faten Hayder, Rim Chaabouni, Meriem Amouri, Abderrahmen Masmoudi, Madiha Mseddi, Sonia Boudeya, Hamida Turki
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare drug reaction characterized by a skin rash, eosinophilia, and organ involvement. Objective: Our purpose is to focus on the clinical and epidemiological characteristics of DRESS in the elderly and to identify the incriminated drugs. Methods: This is a retrospective study including patients, hospitalized for DRESS with
-
Analysis of Contact Allergens in Polyvinyl Chloride Examination Gloves in the United States. Dermatitis (IF 5.2) Pub Date : 2023-09-05 Thomas Norman, Jana Guenther, Isaac Asante, Brandon L Adler
Background: Polyvinyl chloride (PVC) gloves are recommended as a safe alternative for patients with rubber accelerator allergy. However, allergic contact dermatitis to other chemicals in PVC gloves has been reported. Objective: To analyze single-use PVC medical examination gloves in the United States for the presence of potential contact allergens. Methods: Using liquid chromatography-mass spectrometry
-
Prayer-Related Dermatoses in Muslims. Dermatitis (IF 5.2) Pub Date : 2023-08-31 Yousef Salem, Syed Minhaj Rahman, Mojahed Shalabi, Aamir Hussain
Prayer rituals are an integral part of the daily lives of Muslims worldwide. This comprehensive review aims to explore the common dermatoses associated with prayer among Muslims and provide insights for dermatologists to facilitate accurate diagnosis and reduce unnecessary investigations. A systematic literature search returned 367 published articles, of which 21 met the inclusion criteria. Friction-induced
-
Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis. Dermatitis (IF 5.2) Pub Date : 2023-08-01 Shanthi Narla, Jonathan I Silverberg
Recently, 3 oral Janus kinase (JAK) inhibitors-abrocitinib, baricitinib, and upadacitinib-were approved in many regions around the world for the treatment of moderate-severe atopic dermatitis (AD). These JAK inhibitors generally have rapid onset of action and short half-life. Higher doses of abrocitinib and upadactinib even demonstrated superior efficacy to dupilumab. However, JAK inhibitors can be
-
Patch Testing to Paraphenylenediamine: The North American Contact Dermatitis Group Experience (1994-2018). Dermatitis (IF 5.2) Pub Date : 2023-07-31 Erin M Warshaw, Malina Yamashita Peterson, Amber R Atwater, Joel G DeKoven, Melanie D Pratt, James S Taylor, Donald V Belsito, Jonathan I Silverberg, Margo J Reeder, Vincent A DeLeo, Marie-Claude Houle, Cory A Dunnick, Jiade Yu, Brandon Adler, Christen Mowad, Nina C Botto
Background/Objectives: Paraphenylenediamine (PPD) is an aromatic amine dye that may cause allergic contact dermatitis. This study examines the epidemiology of allergic patch test reactions to PPD. Methods: This retrospective analysis characterizes individuals tested to PPD (1% petrolatum) by the North American Contact Dermatitis Group (1994-2018). Demographics and dermatitis site(s) were compared between
-
Hair Dyes Sensitization and Cross-Reactions: Challenges and Solutions: A Systematic Review of Hair Dye Allergens' Prevalence. Dermatitis (IF 5.2) Pub Date : 2023-06-23 Antonios Tsimpidakis, Alexandros Katoulis, Electra Nicolaidou, Dimitrios Rigopoulos, Alexander Stratigos, Stamatis Gregoriou
Widespread use of oxidative hair dyes during the past decades has raised questions on the potential allergy reactions and their management, as well as prevention measures for both professionals and consumers. Allergic contact dermatitis can be elicited by various hair dye-related allergens, though the main problem remains with p-phenylenediamine and related aromatic amines. If allergy is suspected
-
Potential for Allergic Contact Dermatitis in Popular Hair Care Practices and Ingredients. Dermatitis (IF 5.2) Pub Date : 2023-06-20 Maria Karim, Elizabeth J Klein, Ambika Nohria, Dolly Taiwo, Prince Adotama, David Cohen, Jerry Shapiro, Emily Milam, Kristen Lo Sicco
The incidence of allergic contact dermatitis (ACD) due to personal care products is rising in parallel with increasing product availability and consumer interest. Hair products specifically represent a significant source of potential allergens, including preservatives, surfactants, emulsifiers, fragrances, adhesives, and dyes. ACD due to hair care products can present as dermatitis in the distinctive
-
Contact Dermatitis to Ophthalmic Solutions: An Update. Dermatitis (IF 5.2) Pub Date : 2023-06-15 Sally J Ashton, Avad A Mughal
Eyelid and periorbital dermatitis remains a distressing and recalcitrant disease. Contact dermatitis remains the most common cause of eyelid and periorbital dermatitis. Ophthalmic solutions used in the treatment of ophthalmic conditions can often be the cause. This article is an update of our previous study, summarizing the contact allergens involved and the new test concentrations reported to investigate
-
Patch Testing to Chlorhexidine Digluconate, 1% Aqueous: North American Contact Dermatitis Group Experience, 2015-2020. Dermatitis (IF 5.2) Pub Date : 2023-06-06 Erin M Warshaw, Joohee Han, Sara A Kullberg, Joel G DeKoven, Brandon L Adler, Jonathan I Silverberg, Marie-Claude Houle, Melanie D Pratt, Donald V Belsito, Jiade Yu, Nina C Botto, Margo J Reeder, James S Taylor, Amber R Atwater, Cory A Dunnick, Vincent A DeLeo, Chris M Mowad
Background: Chlorhexidine is an antiseptic that may cause allergic contact dermatitis. Objectives: To describe the epidemiology of chlorhexidine allergy and characterize positive patch test reactions. Methods: This retrospective study analyzed patients patch tested to chlorhexidine digluconate 1% aqueous by the North American Contact Dermatitis Group, 2015-2020. Results: Of 14,731 patients tested to
-
Development of an Eczema Area and Severity Index Atlas for Diverse Skin Types. Dermatitis (IF 5.2) Pub Date : 2023-06-06 Jonathan I Silverberg, Joshua Horeczko, Andrew Alexis
Background: Current guidance for using Eczema Area and Severity Index (EASI) implementation is limited to lighter skin phototypes. We developed an EASI lesion severity atlas and refined guidance for investigators and clinicians to use across diverse patient populations. Methods: A review was performed of clinical images from internal atopic dermatitis (AD) photorepositories. Representative images of
-
Patch Testing Results From the Massachusetts General Hospital Occupational and Contact Dermatitis Clinic, 2017-2022. Dermatitis (IF 5.2) Pub Date : 2023-05-24 Hadley Johnson, JiaDe Yu
Background: Patch testing is gold standard for identifying the source of allergic contact dermatitis (ACD). Objective: To report patch testing results from the Massachusetts General Hospital (MGH) Occupational and Contact Dermatitis Clinic from 2017 to 2022. Methods: Retrospective analysis of patients referred to MGH for patch testing, 2017-2022. Results: In total, 1438 patients were included. At least
-
The Characteristics of Allergic Contact Dermatitis in Military and Civilian Populations: A Multicenter Cross-Sectional Study. Dermatitis (IF 5.2) Pub Date : 2023-05-23 Ira Plotnik, Jonathan Bar, Efrat Solomon-Cohen, Michal Solomon, Shlomo Moshe, Dan Slodownik
Background: Contact dermatitis is a common condition in the general population, with a global prevalence of 20%. It is an inflammatory skin disease that is classified as irritant contact dermatitis (80%) and allergic contact dermatitis (ACD) (20%). In addition, it is the most common presentation of occupational dermatoses and is one of the primary reasons for seeking medical attention among military
-
A Review of Dupilumab-Induced Adverse Events to Dermatologists and the Potential Pathogenesis in the Treatment of Atopic Dermatitis. Dermatitis (IF 5.2) Pub Date : 2023-05-19 Jun-Hong Tsai, Tsen-Fang Tsai
Dupilumab, a monoclonal antibody targeting interleukin-4 antibody, is approved for use in many type 2 inflammatory diseases, including atopic dermatitis. It is generally well tolerated with no need of routine laboratory monitoring. However, several adverse events have been reported during real-world practice and in pivotal trials. We conducted a systematic literature research of the PubMed, Medline
-
The Frequency and Utility of Drug Cessation Trials in Older Adults With Chronic Eczematous Dermatitis of Unknown Etiology: A Retrospective Cohort Study. Dermatitis (IF 5.2) Pub Date : 2023-05-12 Amy M Hopkins, Kimberly Lerner, Erin Grinich, Jiyoung Ahn, Yusung Choi, Jon Hanifin, Eric Simpson
Background: Eczematous dermatitis is a major cause of recalcitrant pruritic eruptions in older adults. Although some medications have been implicated, there are limited data demonstrating the utility of medication changes. Objective: To investigate the utility and possible harms of drug cessation trials (DCTs) in chronic eczematous eruptions in the aging (CEEA). Methods: This is a retrospective cohort
-
Occupational Hand Dermatitis in Health Care: Development and Evaluation of an Online Training E-Module. Dermatitis (IF 5.2) Pub Date : 2023-05-08 Katherine A P Zagrodney, Emily C King, Emmelie T C L Mohammed, Kathryn A Nichol, D Linn Holness
Background: Occupational hand dermatitis (OHD) is an important health concern for health care workers (HCWs), yet there is a lack of accessible training materials on this topic. Objectives: The objective of this study was to develop and evaluate an OHD training e-module for HCWs. Methods: The e-module was created in collaboration with an expert advisory committee and tested by Ontario HCWs through
-
The Diagnostic Value of Delayed-Type Reactions to Perennial Aeroallergens for Atopic Disease. Dermatitis (IF 5.2) Pub Date : 2023-05-03 Puneet Arora, Rebecca L Freese, Paul L Bigliardi
Background: Delayed-type reactions to aeroallergens have been observed, however, their clinical significance continues to be debated. Objective: We assessed the prevalence and significance of delayed-type reactions to aeroallergens in atopic patients. Methods: Retrospective study including 266 patients with history or evidence of atopic disease (atopic dermatitis [AD], allergic rhinitis, and/or allergic
-
A Retrospective Analysis of Risk Factors for Atopic Dermatitis Severity. Dermatitis (IF 5.2) Pub Date : 2023-04-26 Min Luo, Huichun C Su, Jinger E Lin, Changhua H Zhu, Lihang H Lin, Yue Han
Background: Atopic dermatitis (AD) has the highest burden of any skin disease; however, the severity-associated factors remain unclear. Objective: To evaluate potential severity-associated factors of AD and to design and validate a severity prediction model to inform the management of AD patients. Methods: A cross-sectional study of 900 AD patients was conducted from December 2021 to October 2022 at
-
Trends in Health Care Utilization Among United States Children With Eczema by Age, Sex, Race, and Hispanic Ethnicity: National Health Interview Survey 2006-2018. Dermatitis (IF 5.2) Pub Date : 2023-04-25 Siri Choragudi, Luis F Andrade, Jonathan Silverberg, Gil Yosipovitch
Background: Higher health care utilization has been proven among US children with eczema than those without, but disparities may exist among sociodemographic subgroups. Objective: To determine health care utilization trends among children with eczema across sociodemographic factors. Methods: We included children (0-17 years old) from the US National Health Interview Survey 2006-2018. We calculated
-
Atopic Dermatitis as a Risk Factor for Herpes Zoster Infection Independent of Treatment: A Nationwide Population-Based Cohort Study. Dermatitis (IF 5.2) Pub Date : 2023-04-19 Shou-En Wu, Yi-Hsien Chen, Chi-Hsiang Chung, Gwo-Jang Wu, Chang-Huei Tsao, Chien-An Sun, Wu-Chien Chien, Chih-Tsung Hung
Background: In the wake of the emerging development of biologics in atopic dermatitis (AD), herpes zoster (HZ) infection has been reported as a treatment-related adverse event. Objectives: This study aims at investigating the association between AD and HZ, and the risk factors within. Methods: 28,677 participants with AD from the Taiwan National Health Insurance Research Database 2000-2015 were enrolled
-
Which Clinical Measurement Tools for Atopic Dermatitis Severity Make the Most Sense in Clinical Practice? Dermatitis (IF 5.2) Pub Date : 2023-04-11 Shanthi Narla, Jonathan I Silverberg
Assessment of atopic dermatitis (AD) severity is essential for therapeutic decision making and monitoring treatment progress. However, there are a myriad of clinical measurement tools available, some of which are impractical for routine clinical use despite being recommended for clinical trials in AD. For measurement tools to be used in clinical practice, they should be valid, reliable, rapidly completed
-
Atopic Dermatitis in Children in the General Population: Baseline Characteristics, Medication Use, and Severity Measures in the Rotterdam Eczema Study. Dermatitis (IF 5.2) Pub Date : 2023-04-04 Karlijn F van Halewijn, Floor van der Most, Arthur M Bohnen, Suzanne G M A Pasmans, Patrick J E Bindels, Gijs Elshout
Background: Real-life data on severity and treatments in children with atopic dermatitis (AD) are needed to evaluate self-management. Objectives: To determine severity and use of topical treatments in children with AD in the general population. Furthermore, we aim to determine agreement and correlation between objective and subjective AD severity measures. Methods: Data were used from the Rotterdam
-
Lanolin. Dermatitis (IF 5.2) Pub Date : 2023-3-15 Blair A Jenkins, Donald V Belsito
Lanolin is a complex mixture of high molecular weight esters, aliphatic alcohols, sterols, fatty acids, and hydrocarbons that has been widely used for centuries for its emollient properties. The purification of crude lanolin into lanolin wax and the processing of this wax into various derivatives began in 1882 and continue to this day with newer highly purified anhydrous lanolins. Controversy as to